Effect Of J-valve For Treatment Of Native Aortic Regurgitation (NAV) On Left Ventricular (LV) Ejection Fraction (EF) And LV Geometry. A Single Center Compassionate Use Study

Severe aortic regurgitation (AR) is the indication for 20-30% of surgical aortic valve replacements and is associated with increased morbidity and mortality. No transcatheter device has received U.S. approval for the treatment of AR. J-valve is a short frame, self-expanding TAVR device specifically designed for treatment of severe AR (Figure 1A). LV pressure overload can result in alterations of LV geometry. The four resulting categories are: normal, concentric hypertrophy (CH), eccentric hypertrophy (EH), and concentric remodeling (CR).

Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Hanad Bashir, Cassady Palmer, Christian Schmidt, Santiago Garcia, Dean J. Kereiakes, Eugene Chung Tags: 022 Source Type: research